Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04631601 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04631601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04631601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Terminated
Start date
January 15, 2021
Completion date
October 23, 2023
Enrollment
55 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer